A 16-Week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of nateglinide vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone).

Trial Profile

A 16-Week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of nateglinide vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone).

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Nateglinide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Apr 2012 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
    • 18 Sep 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top